PASADENA, Calif.--(BUSINESS WIRE)--Genervon Biopharmaceuticals LLC (“Genervon”) today announced that it has completed the analysis of its Phase 2a double blinded, randomized, placebo controlled clinical trials of Amyotrophic Lateral Sclerosis (“ALS”)(NCT01854294) and Parkinson’s disease (“PD”)(NCT 01850381) for its drug candidate GM6 (also known as GM604 in the ALS trial and GM608 in the PD trial). Genervon has received both fast track and orphan drug designations for GM 604 in the treatment of ALS. Genervon has submitted the results of these trials to the FDA for guidance on how to make GM6 available as a therapeutic ALS and PD drug.
Help employers find you! Check out all the jobs and post your resume.
